Chairpersons of the hospital ethics committees (HECs) and BMT clinicians were compared with regard to their willingness to proceed with allogeneic BMT given select psychosocial risk factors. A self-administered questionnaire was sent to 62 HEC chairpersons at hospitals with an accredited BMT program; the response rate was 37%. Items included background information, followed by six case vignettes from a 2006 national survey on which BMT physicians, nurses and social workers agreed not to proceed with allogeneic BMT on the basis of the following risk factors: suicidal ideation; use of addictive, illicit drugs; history of non-compliance; absence of a caregiver; alcoholism; and mild dementia from early onset of Alzheimer's disease. Opinions regarding transplant differed in one case only, in a patient with mild dementia; 27% of HEC chairpersons recommended not proceeding with BMT, which was significantly lower than that of nurses (68%, Po0.001), physicians (63.5%, Po0.001) and social workers (51.9%, P ¼ 0.05). Qualitative data show patterns of informal reasoning, linking transplant decisions to patient's responsibility for their psychosocial risk factor(s), as well as to medical benefit and outcome.
Introduction
Virtually all protocols in BMT have eligibility based on biomedical criteria. 1 Increasingly, psychosocial issues are being included in the discussion of patient selection. Reasoning behind such discussions seems clinical, such as the perceived acuity and severity of the psychosocial risk factor, patient's ability to comply with treatment protocols given the risk factor, and its manageability for treatmentrelated vulnerability and outcomes. 2 Although either associated with or predictive of patient outcomes in BMT, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] psychosocial selection criteria raise concern that such criteria might 'y unwittingly hide value judgments that could unjustly limit an individual patient's access to treatments.' 16 BMT decisions are often conditional and patients are asked to take responsibility for improving their psychosocial risk factor(s) before proceeding to transplant. 2 Clinical reasoning using psychosocial criteria is consistent with, but secondary to, principles of medical utility when deciding who to transplant to achieve the best possible medical benefit and outcome. Furthermore, inasmuch as accessing BMT is an ethical as well as clinical issue, the inclusion of ethical reasoning is essential. Just as no BMT program wants to risk patients dying because they were less than diligent in patient screening, neither does a program want patients and families angry and upset, questioning the appropriateness and fairness of a 'do not proceed' decision in BMT based on psychosocial risk factors.
On the basis of the authors' clinical experience, BMT clinicians are often conflicted with regard to the ethical issues and questions that denial of BMT raises when constrained by psychosocial risk factor(s). Philosophically, should proceeding with transplant depend on patients taking responsibility for their psychosocial risk factors? Is an element of patient choice in having a risk factor morally relevant in transplant eligibility decisions? When does foreseeable harm because of a psychosocial risk factor justify a 'do not transplant' decision? Practically, is delaying BMT for a patient to go through substance abuse treatment morally justifiable when the patient has a tenuous remission? Is it morally acceptable for a leukemia patient with mild dementia to trade off quality of life for a chance of a cure, but with risks of acute GVHD, resulting in suffering and possible death? Is there a moral difference between a patient dying without BMT and dying because of a BMT owing to non-compliance with treatment protocols or lack of caregiver support?
Access to health-care needs is commonly understood to be an ethical issue, and the gravity of BMT as a potentially life-saving decision begs the question: Are eligibility decisions by clinicians in BMT viewed as ethically sound when patients are denied transplantation based on psychosocial risk factors? Responses and ethical reasoning of chairpersons of hospital ethics committees (HECs) may have some bearing on answering this question. Whether they would agree with decisions of their clinical colleagues in BMT is unknown, as is the nature of their ethical reasoning, including the role of ethical theory and principles in their decision-making. 17 Therefore, this research attempts to address these questions and reports on the responses and ethical reasoning of HEC chairpersons in cases of patients who have been determined, by our earlier published survey of BMT programs, 2 to be inappropriate candidates for allogeneic BMT on the basis of select psychosocial risk factors.
Materials and methods
This survey is a continuation of an earlier published study in which questionnaires were sent to BMT physicians, nurses and social workers regarding their willingness to proceed to allogeneic transplant given select psychosocial risk factors. Among 17 case vignettes presented in that survey, the consensus 'not to proceed' was achieved among the three professional groups for six cases. 2 As a follow-up, these six cases were included in this survey in which a selfadministered questionnaire was sent to HEC chairpersons at hospitals with a BMT program that performs adult allogeneic BMT and is accredited by the Foundation for the Accreditation of Cellular Therapy and designated as a National Marrow Donor Program Transplant Center. The list of HEC chairpersons was developed by calling the eligible hospitals and obtaining the names and mailing addresses; after three mailings, 23 of 62 chairpersons responded to the survey (37%). The questionnaire included background information, a brief overview of allogeneic BMT and the case facts and circumstances in each case vignette. A self-addressed postage-paid envelope was included; both the survey and return envelope were numbered to maintain confidentiality. Approval for the study was obtained from the authors' Institutional Review Board.
Questionnaire items
Respondent background variables include age, gender, position title and years of experience in bioethics. Each respondent was asked to indicate agreement/disagreement with the BMT team's 'do not proceed' decision and to provide a brief statement of reasoning justifying their decision with regard to the six earlier identified psychosocial risk factors: current suicidal ideation, use of addictive illicit drugs, history of being non-compliant with treatment, residing 6 h away from the hospital and having no caregiver, drinking several alcoholic drinks daily and being told he is an alcoholic, and having mild dementia from early onset of Alzheimer's disease; these risk factors are rank-ordered and highlighted in bold in Table 1 .
Case facts and circumstances given in each of the above six cases include the following: allogeneic BMT is the only curative option, the patient has leukemia, a matched donor and both the patient and family want to proceed; the BMT team, including the oncologist, nurse coordinator and social worker, recommends not proceeding to transplant on the basis of the presenting psychosocial risk factor's acuity, severity and manageability; plans for allogeneic BMT are on hold; the patient and family disagree with the team's decision; and they believe that the decision to proceed or not should not be based on psychosocial issues and request an ethics review.
Statistical analysis
Age and years of experience variables were compared among professional groups using analysis of variance. Gender and response to six case vignettes were compared among professional groups using the w 2 -test. Pairwise comparisons of P-values were calculated for variables, which were found to differ among the four professional groups; the only pairwise comparisons of interest were of HEC chairpersons relative to each of the other three professional groups. P-values were not adjusted for multiple comparisons. For each of the six case vignettes, multivariable logistic regression analysis was used to assess HEC chairpersons' opinion of whether to proceed with transplant relative to the other three professional groups after adjusting for three variables that were found to differ among the professional groups (age, gender and years of experience). All analyses were carried out using SAS software. All statistical tests were two sided; Po0.05 was used to indicate statistical significance.
Results

Demographics
With respect to HEC chairpersons' background variables (Table 2) , median age is 54 years, with gender being split (Table 6 ). Also worth noting in case #6 is the fact that 65% or 15 of the 23 HEC chairpersons appealed to medical consequences compared with 9-39% for cases 1-5. Appealing to several consequences, medical and non-medical, a majority (10 of 15) of the 15 appeals by HEC chairpersons were used to justify proceeding to transplant. For the patient with mild dementia, thematic were emotive appeals to potential quality of life, the medical consequences of a 'do not transplant' decision and the importance of family wishes and support. In the words of one HEC chairperson, 'If the patient can still enjoy his garden time with family, and he has a dedicated caregiver who will make sure he adheres to treatment, then proceed. ' Although HEC chairpersons' decisions in the first five cases also appealed to ethical rules and principles, their decisions were more likely to appeal to a combination of medical and non-medical consequences and other casebased considerations as constraints for transplant (that is, need for psychiatry evaluation, intervention for substance abuse, improving patient compliance, obtaining caregiver support and following BMT program policies). These constraints for transplant require the patient and/or family to ameliorate the psychosocial risk factor before proceeding to BMT. Regarding case #4, HEC chairpersons agreed with the importance of having a lay caregiver before proceeding to transplant; only one of the six respondents who invoke BMT policy recommended transplant. Qualifying this agreement, most felt that finding a caregiver or providing facilities for aftercare near the hospital was a BMT program's responsibility; as two respondents commented: 'It seems having an after-care facility is a prerequisite for a transplant program. Refusing such a patient risks serious inequities-privileged patients will rarely be in such a situation. It is the team's job to find the support he needs.'
Discussion
The HEC chairperson response rate of 37% may be perceived as a limitation of the study, a concern perhaps made more apparent by the small number (N ¼ 62) of hospitals with an accredited BMT program that transplants adult allogeneic patients. One may also wonder if their decisions regarding the cases would be the same if the BMT clinicians' decision to not proceed with transplant had been blinded. However, in practice, HEC chairpersons are informed of such case facts and circumstances before case review by HEC. Nevertheless, the fact that HEC chairpersons concur with BMT clinicians' 'do not proceed' to transplant decisions on five of the six study cases may reflect, according to one HEC chairperson, 'reluctance to attempt to over-rule a clinician and force that professional to do something they felt was wrong. ' HEC chairpersons' willingness to disagree with clinicians in the case of mild dementia may reflect different understandings or views of the prognosis and quality of life for early-onset Alzheimer patients in the context of allogeneic BMT. Although BMT clinicians witness the intensity of post-transplant complications and demands of treatment on a regular basis, HEC chairpersons do not. Although BMT clinicians in the initial phase of the study viewed mild dementia as a constraint to proceeding with allogeneic BMT, citing burdensome care and compliance concerns, HEC chairpersons seem to view mild dementia as amenable to being managed, given adequate family support. Specifically, appeals to the ethical principle of quality of life, combined with appeals to such considerations as family and lay caregiver support and the desire to honor family wishes, may have combined to mitigate viewing dementia as a constraint in BMT. Philosophically, the ideal of maximizing potential to 'do good' is often in conflict with the bedside reality of minimizing harms to a patient lacking potential decisional capacity. The fact that HEC chairpersons disagree with BMT clinicians in the case of mild dementia but agree with the 'do not transplant' decision on the other five cases may be because of differing perceptions of patient responsibility for their risk factors. According to the literature on responsibility and health, there are two varieties of responsibility: take-charge responsibility and just-deserts responsibility; the former is responsibility 'ythat patients can and should take for their own healthcare y' and the latter posits 'ythat patients who bring illness on themselves by their autonomous choices are less deserving of optimum treatment.' 18 Although the conditional nature of transplant decisions suggests that patients/families should take responsibility for their risk factors before proceeding to transplant, this is not evidence that BMT programs subscribe to a 'just-deserts' responsibility nor do we believe that this is made legitimate, secretly, in practice.
Rather, compared with patients who use addictive and illicit drugs, who are suicidal, alcoholic and/or noncompliant, patients with mild dementia may be viewed by HEC chairpersons as not having an element of choice and not personally responsible for their risk factor and, thus, more deserving of BMT from a medical utility perspective. Furthermore, non-compliance with BMT policy, which requires a caregiver, may be perceived as a risk factor having an element of choice on the part of the patient and/ or the family, which may explain HEC chairpersons' unwillingness to transplant patients without a caregiver. On the basis of the authors' clinical experience in BMT, patients/families vary in their motivation, ability and opportunity to come up with a caregiver plan, and there are always choices to consider, albeit difficult ones, choices a patient with dementia does not have.
The use of philosophical and rule-/principle-based ethical reasoning by HEC chairpersons to justify their transplant decisions was an unconfirmed expectation. Instead, their use of emotive and social considerations, including patient's needs and family wishes, suggests patterns of informal reasoning. 19 Only when justifying their disagreement with BMT clinicians on case #6 (mild dementia/Alzheimer's disease) do HEC chairpersons seem to rely more on appeals to ethical rules/principles in their reasoning. Compared with the other five cases, they may have experienced more of a quandary or 'ethical moment' marked by uncertainty and a struggle with their decision and, thus, the need to rely on ethical rules/principles. Otherwise, the qualitative findings suggest that HEC chairpersons tend to appropriate rather than directly apply philosophical rules and principles in their reasoning, a finding consistent with arguments in the ethics literature. 20 This is also consistent with the assertion of no correlation between ethics education in moral philosophy and moral decision-making in hospital ethics contexts. 17 Thus, the finding that both HEC chairpersons in this study and clinicians in the earlier study appeal primarily to pragmatic considerations in their transplant decisions is not surprising.
Although historically BMT has not been a context for empirical study of ethics, study findings suggest that ethics consults, reasoning and discussions that are pragmatic, patient-centered and family-based may prove to be helpful resources for clinicians when patients and families disagree with a program's decision to base eligibility on psychosocial Table 6 Frequency of reasons given by HEC chairpersons for agreeing/disagreeing with BMT programs' 'do not proceed' decisions based on psychosocial risk factors-cases 1-6
Reasons cited
Case #1 Case #2 Case #3 Case #4 Case #5 Case #6 criteria. Hopefully, our research generates more reflective discussion with regard to the access to BMT as an ethical as well as clinical issue. As a result of such discussions, concerns that psychosocial criteria might unwittingly hide value judgments, influencing patient access to BMT, may be mitigated, and BMT programs may be better prepared to defend patient eligibility decisions based on psychosocial as well as biomedical criteria. As psychosocial factors are increasingly being considered in BMT protocols, educating patients and families regarding the linkages between these risk factors and medical outcomes should be a priority.
